PD-L1 positive MSDs with LILs were generally associated with high BMT or number of neoantigens in multiple tumours, so these cancers would benefit from anti-PD-1/PD-L1 therapies, as these tumours have evidence of pre-existing intra-tumoral T cells being inactivated by compromised PD-L1 [322,334]. The gene discussed is CD274; the disease is neoplasm.